131 related articles for article (PubMed ID: 2626803)
1. The beige mouse model for Mycobacterium avium complex (MAC) disease: optimal conditions for the host and parasite.
Gangadharam PR; Perumal VK; Farhi DC; LaBrecque J
Tubercle; 1989 Dec; 70(4):257-71. PubMed ID: 2626803
[TBL] [Abstract][Full Text] [Related]
2. Liposomal amikacin: improved treatment of Mycobacterium avium complex infection in the beige mouse model.
Petersen EA; Grayson JB; Hersh EM; Dorr RT; Chiang SM; Oka M; Proffitt RT
J Antimicrob Chemother; 1996 Nov; 38(5):819-28. PubMed ID: 8961051
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic efficacy of liposomal clofazimine against Mycobacterium avium complex in mice depends on size of initial inoculum and duration of infection.
Kansal RG; Gomez-Flores R; Sinha I; Mehta RT
Antimicrob Agents Chemother; 1997 Jan; 41(1):17-23. PubMed ID: 8980748
[TBL] [Abstract][Full Text] [Related]
4. Characterization of mouse models of Mycobacterium avium complex infection and evaluation of drug combinations.
Andréjak C; Almeida DV; Tyagi S; Converse PJ; Ammerman NC; Grosset JH
Antimicrob Agents Chemother; 2015 Apr; 59(4):2129-35. PubMed ID: 25624335
[TBL] [Abstract][Full Text] [Related]
5. Contributions of animal and macrophage models to the understanding of host parasite interaction of Mycobacterium avium complex (MAC) disease.
Gangadharam PR; Reddy MV
Res Microbiol; 1994; 145(3):214-24. PubMed ID: 7809475
[No Abstract] [Full Text] [Related]
6. Liposome encapsulation of clofazimine reduces toxicity in vitro and in vivo and improves therapeutic efficacy in the beige mouse model of disseminated Mycobacterium avium-M. intracellulare complex infection.
Mehta RT
Antimicrob Agents Chemother; 1996 Aug; 40(8):1893-902. PubMed ID: 8843300
[TBL] [Abstract][Full Text] [Related]
7. Development of an in vivo-mimic silkworm infection model with Mycobacterium avium complex.
Yagi A; Yamazaki H; Terahara T; Yang T; Hamamoto H; Imada C; Tomoda H; Uchida R
Drug Discov Ther; 2021 Jan; 14(6):287-295. PubMed ID: 33250497
[TBL] [Abstract][Full Text] [Related]
8. Virulence of Mycobacterium avium complex strains from acquired immune deficiency syndrome patients: relationship with characteristics of the parasite and host.
Gangadharam PR; Perumal VK; Jairam BT; Podapati NR; Taylor RB; LaBrecque JF
Microb Pathog; 1989 Oct; 7(4):263-78. PubMed ID: 2695739
[TBL] [Abstract][Full Text] [Related]
9. Activity of ABT-773 against Mycobacterium avium complex in the beige mouse model.
Cynamon MH; Carter JL; Shoen CM
Antimicrob Agents Chemother; 2000 Oct; 44(10):2895-6. PubMed ID: 10991883
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex infection induced in mice.
Tomioka H; Saito H; Sato K; Yamane T; Yamashita K; Hosoe K; Fujii K; Hidaka T
Antimicrob Agents Chemother; 1992 Feb; 36(2):387-93. PubMed ID: 1605603
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Clinical Features, Virulence, and Relapse among Mycobacterium avium Complex Species.
Boyle DP; Zembower TR; Reddy S; Qi C
Am J Respir Crit Care Med; 2015 Jun; 191(11):1310-7. PubMed ID: 25835090
[TBL] [Abstract][Full Text] [Related]
12. Activities of bay Y 3118, levofloxacin, and ofloxacin alone or in combination with ethambutol against Mycobacterium avium complex in vitro, in human macrophages, and in beige mice.
Bermudez LE; Inderlied CB; Kolonoski P; Wu M; Barbara-Burnham L; Young LS
Antimicrob Agents Chemother; 1996 Mar; 40(3):546-51. PubMed ID: 8851568
[TBL] [Abstract][Full Text] [Related]
13. Assessment of new therapies for infection due to the Mycobacterium avium complex: appropriate use of in vitro and in vivo testing.
Grosset JH
Clin Infect Dis; 1994 Apr; 18 Suppl 3():S233-6. PubMed ID: 8204775
[TBL] [Abstract][Full Text] [Related]
14. Comparison of virulence of Mycobacterium avium complex (MAC) strains isolated from AIDS and non-AIDS patients.
Reddy VM; Parikh K; Luna-Herrera J; Falkinham JO; Brown S; Gangadharam PR
Microb Pathog; 1994 Feb; 16(2):121-30. PubMed ID: 8047000
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapeutic potential of free and liposome encapsulated streptomycin against experimental Mycobacterium avium complex infections in beige mice.
Gangadharam PR; Ashtekar DA; Ghori N; Goldstein JA; Debs RJ; Düzgünes N
J Antimicrob Chemother; 1991 Sep; 28(3):425-35. PubMed ID: 1960123
[TBL] [Abstract][Full Text] [Related]
16. Amikacin, ciprofloxacin, and imipenem treatment for disseminated Mycobacterium avium complex infection of beige mice.
Inderlied CB; Kolonoski PT; Wu M; Young LS
Antimicrob Agents Chemother; 1989 Feb; 33(2):176-80. PubMed ID: 2719461
[TBL] [Abstract][Full Text] [Related]
17. Minocycline treatment for pulmonary Mycobacterium avium complex disease based on pharmacokinetics/pharmacodynamics and Bayesian framework mathematical models.
Ruth MM; Magombedze G; Gumbo T; Bendet P; Sangen JJN; Zweijpfenning S; Hoefsloot W; Pennings L; Koeken VACM; Wertheim HFL; Lee PS; van Ingen J; Deshpande D
J Antimicrob Chemother; 2019 Jul; 74(7):1952-1961. PubMed ID: 31039251
[TBL] [Abstract][Full Text] [Related]
18. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates.
Kobashi Y; Yoshida K; Miyashita N; Niki Y; Oka M
J Infect Chemother; 2006 Aug; 12(4):195-202. PubMed ID: 16944258
[TBL] [Abstract][Full Text] [Related]
19. Effect of ethambutol on emergence of clarithromycin-resistant Mycobacterium avium complex in the beige mouse model.
Bermudez LE; Nash KA; Petrofsky M; Young LS; Inderlied CB
J Infect Dis; 1996 Dec; 174(6):1218-22. PubMed ID: 8940212
[TBL] [Abstract][Full Text] [Related]
20. Prevention of the selection of clarithromycin-resistant Mycobacterium avium-intracellulare complex.
Grosset J; Ji B
Drugs; 1997; 54 Suppl 2():23-7; discussion 28-9. PubMed ID: 9358197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
